Nano Cap New Millennium Growth Fund L P Purchases New Position in CRISPR Therapeutics AG $CRSP

Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 17,500 shares of the company’s stock, valued at approximately $918,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. increased its position in shares of CRISPR Therapeutics by 5.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company’s stock valued at $228,000 after buying an additional 180 shares during the period. Cerity Partners LLC grew its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company’s stock worth $318,000 after purchasing an additional 190 shares during the period. Peapack Gladstone Financial Corp grew its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company’s stock worth $339,000 after purchasing an additional 200 shares during the period. Optiver Holding B.V. grew its holdings in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares during the period. Finally, US Bancorp DE grew its holdings in CRISPR Therapeutics by 4.5% in the third quarter. US Bancorp DE now owns 5,777 shares of the company’s stock worth $374,000 after purchasing an additional 249 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent research reports. Needham & Company LLC upped their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, February 13th. Bank of America cut their price objective on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Citizens Jmp cut their price objective on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating on the stock in a report on Friday, January 30th. TD Cowen upped their price objective on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Finally, Wall Street Zen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.47.

Insider Transactions at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,150 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $48.26, for a total value of $152,019.00. Following the transaction, the insider owned 13,143 shares in the company, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 10,349 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total transaction of $499,442.74. Following the completion of the transaction, the chief executive officer owned 245,834 shares in the company, valued at approximately $11,863,948.84. This represents a 4.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 42,749 shares of company stock worth $2,100,723. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Trading Up 2.8%

Shares of NASDAQ CRSP opened at $49.90 on Friday. The firm’s 50 day moving average price is $50.87 and its 200-day moving average price is $53.28. The company has a market cap of $4.81 billion, a PE ratio of -8.02 and a beta of 1.74. CRISPR Therapeutics AG has a 52-week low of $35.38 and a 52-week high of $78.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.46 million during the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. On average, equities research analysts expect that CRISPR Therapeutics AG will post -5.08 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.